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Inkoo	virus	(INKV)	and	Chatanga	virus	(CHATV),	which	are	
circulating	 in	 Finland,	 are	mosquitoborne	 California	 sero-
group orthobunyaviruses that have a high seroprevalence 
among	humans.	Worldwide,	INKV	infection	has	been	poorly	
described,	 and	 CHATV	 infection	 has	 been	 unknown.	 Us-
ing	serum	samples	collected	in	Finland	from	7,961	patients	
suspected	 of	 having	 viral	 neurologic	 disease	 or	 Puumala	
virus	infection	during	the	summers	of	2001–2013,	we	ana-
lyzed	the	samples	to	detect	California	serogroup	infections.	
IgM	seropositivity	revealed	17	acute	infections,	and	cross-
neutralization	tests	confirmed	presence	of	INKV	or	CHATV	
infections.	All	children	(<16	years	of	age)	with	INKV	infec-
tion	 were	 hospitalized;	 adults	 were	 outpatients	 with	 mild	
disease,	 except	 for	 1	 who	 was	 hospitalized	 with	 CHATV	
infection.	 Symptoms	 included	 fever,	 influenza-like	 illness,	
nausea or vomiting, disorientation, nuchal rigidity, head-
ache,	drowsiness,	and	seizures.	Although	many	INKV	and	
CHATV	 infections	 appear	 to	 be	 subclinical,	 these	 viruses	
can cause more severe disease, especially in children.
Inkoo virus (INKV) and Chatanga virus (CHATV) are 2 members of the California serogroup of orthobunyavi-
ruses that are currently found in Finland. They are triseg-
mented, enveloped negative-strand RNA viruses belonging 
to genus Orthobunyavirus (family Bunyaviridae), which in-
cludes several recognized mosquitoborne human pathogens. 
INKV was first isolated from Ochlerotatus communis 
and O. punctor mosquitoes in 1964 in Finland (1) and has 
since been found in Sweden, Norway, and Russia (2–4). The 
high seroprevalence in these countries suggests that INKV 
infections are common in these locations (5–8). Although 
the virus has been known to occur in Finland for decades, 
only 1 domestic report describes a possible association of 
INKV to clinical disease (9). Reports from Russia show 
INKV IgM or neutralizing antibodies in patients with neu-
rologic symptoms or fever, but only 2 cases were identified 
as INKV infection; most often, the California serogroup vi-
rus infections were caused by Tahyna virus (TAHV), or the 
infecting virus could not be defined (10–12). 
CHATV was isolated from mosquitoes collected in 
Finland in 2007 (13) but is known to have circulated earlier 
in Russia, where the first characterized isolate was from 
a mosquito collected in 1987 (14). CHATV strains have 
≈84% aa identity with INKV within the nucleocapsid pro-
tein but are more similar to the Snowshoe hare virus (93% 
nucleocapsid protein identity) that occurs in the United 
States. We found no previous reports of CHATV infections 
naturally occurring in humans or animals.
Patients with California serogroup virus infections 
usually remain asymptomatic or have symptoms of mild 
influenza-like illness, but some of these viruses may also 
cause encephalitis (15–17). The California serogroup vi-
ruses cross-react on many serologic tests, so neutralization 
assays are required to verify the specific virus. In the United 
States, 29–167 cases of California serogroup virus enceph-
alitis are diagnosed annually, and most cases result from 
La Crosse virus (LACV) (18), which is one of the most 
important arboviral agents causing encephalitis in children 
in the United States but is rarely found in adults. This pat-
tern contrasts with the arbovirus West Nile virus, which 
causes central nervous system (CNS) infections in adults 
more often than in children (19). LACV encephalitis can 
be mistaken for herpes simplex virus (HSV) or enterovi-
rus meningoencephalitis and is often undiagnosed (15,20). 
Other California serogroup viruses that cause neuroinva-
sive disease in the United States and Canada are California 
encephalitis, Jamestown Canyon, and Snowshoe hare vi-
ruses (17,21–24), although infections caused by these vi-
ruses are reported more rarely than those caused by LACV 
and are not as extensively studied.
The incidence of California serogroup virus infections 
in Europe is largely unknown because of underdiagnosing 
and underreporting that result from lack of alertness among 
healthcare workers and lack of surveillance efforts. Avail-
able data indicate that TAHV has the most widespread dis-
tribution in Europe and is mostly asymptomatic or causes 
febrile illness, especially in children (16,25,26).
Because pathogens that cause encephalitis during the 
summer months in Finland are mostly unknown (27), we 
attempted to study the occurrence of acute California sero-
group virus infections, particularly those caused by INKV, 
in febrile and encephalitic patients during the mosquito 
season in Finland and to characterize those infections. We 
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report our observance of INKV and CHATV infections in 
humans and describe the clinical characteristics of acute in-
fections caused by these viruses.
Methods and Materials 
Patient Samples
Our analysis comprised 3 sets of patient samples (7,961 
total patients). First, we retrospectively screened serum 
samples that were collected from patients in healthcare 
facilities across Finland during the summer months of 
2001–2013 (Table 1) and were sent as diagnostic samples 
to the Department of Virology and Immunology, Helsinki 
University Central Hospital Laboratory, Hospital District 
of Helsinki and Uusimaa (institutional review board permit 
119/E0/05). For patients presumed to have CNS symptoms, 
samples were screened for antibodies against a panel of 
meningoencephalitis agents (HSV, varicella zoster virus, 
human herpesvirus 6, enterovirus, and Mycoplasma pneu-
moniae bacteria); for patients presumed to have febrile ill-
ness, samples were screened for Puumala virus. For most 
samples, laboratory screening was negative for the viral 
agents studied. In addition to these 2 sample groups, we 
analyzed samples specifically received for screening of 
INKV antibodies during the study period. 
Of the total 8,793 samples we tested for California 
serogroup virus IgM, 4,214 serum samples and 832 cere-
brospinal fluid (CSF) samples had been initially sent for 
screening of meningoencephalitis agents; 3,574 serum 
samples had been initially sent for Puumala virus testing; 
and 173 serum samples had been sent for INKV testing. 
Samples were stored at -20°C; aliquots of the serum sam-
ples were stored at –70°C for PCR testing. Laboratory data 
and patient histories were collected from patient records for 
cases with confirmed California serogroup virus IgM posi-
tivity. Data on 2 previously confirmed cases with INKV 
infection that occurred in 1976 and 1980 were included in 
the analysis; these cases had been confirmed with hemag-
glutination inhibition and neutralization tests, and full pa-
tient histories had been described previously (9).
Serologic Testing
Serum samples were screened with an indirect INKV-
IgM immunofluorescence (IFA) test described previously 
(5). In brief, IFA slides contained Vero E6 cells (green 
monkey kidney cells, American Type Culture Collection, 
CRL-1586, Manassas, VA, USA); 30% of the cells were 
infected with INKV. Samples (serum diluted at 1:20 ratio; 
CSF undiluted) were incubated on slides overnight and 
then washed with phosphate-buffered saline; anti–human 
IgM fluorescein isothiocyanate conjugate was then added, 
and samples were incubated for 1 hour. After being washed 
with phosphate-buffered saline, slides were dried and ex-
amined with a fluorescence microscope. IgM-positive 
samples were retested with IgM IFA after removal of IgG 
by using Gullsorb treatment (Meridian Bioscience, Inc., 
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Table 1.	Serum	samples	screened	for	California	serogroup	virus	IgM	and	IgM-positive samples, by patient group and date of 
collection,	Finland,	2001–2013* 
Patient	group	and	date	of	sample collection† Serum	samples,	no. IgM-positive samples, no. IgM	prevalence,	% 
Suspected	Puumala	virus	infection 
 2001	May	25Sep	4 1,294 2 0.15 
 2004	Jun	14–Sep	1 958 1 0.10 
 2012	Jun	5–Aug	21 498 2 0.40 
 2013	May	16–Sep	26 824 0 0 
 Total 3,574 5 0.14 
Neurologic	symptoms 
 2003	Jun	2–Sep	29 711 2 0.28 
 2004	Jun	10–Sep	17 868 2 0.23 
 2005	Jun	23–Oct	1 969 2 0.21 
 2007	Jun	20–Aug	30 563 0 0 
 2012	Jun	8–Oct	15 1,103 3 0.27 
 Total 4,214 9 0.21 
Suspected	Inkoo	virus	infection 
 2004	 32 1 3.13 
 2005	 30 0 0 
 2006	 21 0 0 
 2007	 31 0 0 
 2008	 11 0 0 
 2009	 15 0 0 
 2010	 16 0 0 
 2011 14 0 0 
 2012 3 0 0 
 Total 173 1 0.58 
All patient groups 7,961 15 0.19 
*Samples	from	patients	were	initially	screened	for	Puumala virus, for agents causing neurologic infections, or Inkoo virus. Indirect immunofluorescence was 
used	to	screen	for	California	serogroup	virus	IgM. 
†Sample collection for suspected Inkoo virus infection was for the entire year.  
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Cincinnati, OH, USA) for the serum samples. To ensure 
that diagnostic criteria of acute infection were met, as pre-
viously described, IgM-positive samples were confirmed 
with IgG IFA testing (5) and studied with INKV prototype 
strain KN3641 (1), CHATV Möhkö strain M07–1 (13), and 
TAHV prototype strain Bardos 92 (28) plaque-reduction 
neutralization test (PRNT) (13). PRNT was performed be-
cause of the occurrence of cross-reactions. 
Reverse Transcription PCR
When possible (i.e., when sufficient sample remained after 
serologic testing), IgM-positive samples were tested with 
reverse transcription PCR (RT-PCR) to study the presence 
and kinetics of viremia and to obtain information on the vi-
ral sequences. RNA extraction was performed by using the 
QIAamp Viral RNA Mini Kit (QIAGEN, Valencia, CA, 
USA) according to the manufacturer’s instructions. The ex-
tracted RNA was reverse transcribed to cDNA with ERT-
Ro Roche Expand Reverse Transcriptase (Roche, India-
napolis, IN, USA). PCR methods, as described previously 
(29,30), were modified to work with the Phusion Flash 
High-Fidelity PCR Master Mix (Thermo Scientific, Grand 
Island, NY, USA). The mixture included 1.25 µL of each 
primer (10 µmol/L), 12.5 µL of the Phusion Flash 2X buf-
fer, and 8 µL of sterile distilled deionized water, producing 
a total volume of 25 µL, which included 2 µL of cDNA.
Results
Our hospital diagnostic laboratory received 7,961 serum 
and 832 CSF samples from 7,961 patients in Finland during 
2001–2013 (Table 1). Samples were initially submitted to 
determine antibodies against either a panel of agents causing 
neurologic infections (4,214 serum and 832 CSF samples), 
Puumala virus (3,574 serum samples), or INKV (173 se-
rum samples) (Table 1). Most (4,299 [54%]) serum samples 
were from healthcare settings in southern Finland. Children 
<10 years of age had the smallest number of samples; adults 
50–59 years of age had the largest number of samples. A 
slight preponderance (52%) of sampled patients were male. 
Including the 2 previously confirmed cases, a total of 
17 serum samples and no CSF samples were found IgM 
positive for California serogroup viruses. Serum samples 
were IgM positive among 0.21% of patients with CNS 
symptoms, 0.14% of patients with suspected Puumala vi-
rus infection, and 0.58% of patients with suspected INKV 
infection (Table 1). Frequency of IgM positivity was sim-
ilar for different years of sample collection. The age range 
of patients with positive results was 7–81 years; 8 patients 
were female and 9 were male. California serogroup virus-
es IgM was found most commonly in patients <19 or 50–
59 years of age (Table 2). Most (88%) IgM-positive cases 
were detected during or after late August. Fourteen (82%) 
of the 17 patients showed the highest neutralizing anti-
body titers (up to 1,280) against INKV, whereas 3 patients 
showed the highest titers (up to 20,480) against CHATV. 
Neutralization tests for 2 of the 3 CHATV patients re-
sulted in titers >4 times those for other studied California 
serogroup viruses, which met the diagnostic criterion for 
confirmed CHATV infection; the third CHATV patient 
with a lower titer likely had CHATV infection (Table 3). 
The earliest that IgM was detectable was day 3 of symp-
tom onset (fever); 1 patient still had detectable IgM 3 
weeks after symptom onset (Table 4). IgM titers varied 
generally between 1:30 and 1:160, and exceeded 1:320 
in only 3 patients. IgG in IFA was detected in most IgM-
positive patients. No patient had detectable California se-
rogroup virus RNA.
Clinical histories were collected for all patients whose 
samples had a positive California serogroup virus IgM result 
(Table 3). Patients could be divided into 2 groups: those with 
a known reason (other than INKV or CHATV  infection) for 
seeking medical care (10/17) and those for whom the cause 
of acute infection was unknown (7/17) (Table 3). The latter 
group of patients were evaluated for California serogroup vi-
rus infection because their medical records showed no other 
cause for their symptoms (i.e., no underlying disease or labo-
ratory findings that implied another infection) (Table 4). All 
4 children (<16 years of age) with an unknown infection had 
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Table 2. Age group and sex of patients whose serum samples were tested and number of samples that were IgM	positive	for	INKV	
and CHATV infections in	Finland,	2001–2013* 
Characteristic Patients,	no.	(%) INKV infection CHATV	infection 
Age range  
 0–9 670	(8.42) 1 0 
 10–19 717	(9.01) 2 0 
 20–29 905	(11.37) 0 0 
 30–39 1062	(13.34) 1 0 
 40–49 1180	(14.82) 2 1 
 50–59 1377	(17.30) 5 1 
 60–69 1093	(13.73) 1 0 
 >70 957	(12.02) 0 1 
Sex  
 F 3802 (47. 76) 8 0 
 M 4159	(52.24) 6 3 
*CHATV,	Chatanga	virus;	INKV,	Inkoo	virus. 
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acute INKV infection, whereas 2 adults with an unidenti-
fied infection had CHATV infection. These 6 patients were 
hospitalized. All had fever and other symptoms such as sore 
throat, nausea and vomiting, and neurologic conditions such 
as disorientation, nuchal rigidity, headache, and drowsiness. 
Small changes in electroencephalography were observed in 
2 patients, and 1 patient had seizures (Tables 4, 5). All pa-
tients fully recovered from the infections.
Of the 17 California serogoup virus infection IgM-
positive patients, 11 were not hospitalized for that infec-
tion. Four of these 11 patients visited a physician only 
once; 6 others were treated for another indication because 
their symptoms were interpreted as resulting from causes 
other than INKV or CHATV infection. Ten (91%) of the 
11 patients who were not hospitalized were >40 years of 
age. Six (55%) of the 11 outpatients had a laboratory-con-
firmed co-infection with another pathogen, such as HSV 
(antigen positive), acute Puumala virus infection (i.e., the 
same serum sample was positive for Puumala virus IgM), 
an Escherichia coli urosepsis, and impetigo contagiosa. 
One patient was reported to have had erythema migrans 4 
weeks before sample collection, yet no antibodies against 
Borrelia burgdorferi were found. One patient suffered a 
back injury 1 week before symptom onset (Table 3).
Discussion
In previous studies, the prevalence of California serogroup 
virus antibodies was high (30%–40%) in Nordic countries 
(5,8). To maintain such a high seroprevalence in Finland, 
>20,000 acute infections would need to occur annually dur-
ing the mosquito season. Worldwide, California serogroup 
viruses other than INKV and CHATV have been associated 
with febrile illnesses and neurologic infection, but these in-
fections have not been characterized in Finland. For that 
purpose, we retrospectively screened panels of serum sam-
ples that were originally collected over a period of years 
during the mosquito season and sent to our diagnostic labo-
ratory for detection of antibodies to either causative agents 
of CNS infection (HSV1, HSV2, human herpesvirus 6, 
varicella zoster virus, Mycoplasma pneumoniae), Puumala 
virus, or INKV.
We estimated the frequency of acute human CHATV 
and INKV infections and characterized symptoms of these 
infections. The 2 patients with confirmed CHATV infec-
tion show that CHATV can cause human infection. We 
found symptoms that were similar to those reported for 
other viruses in the California serogroup. Both INKV and 
CHATV have remained practically unknown among physi-
cians in Finland, and the rate of clinical suspicion has been 
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Table 3. Clinical	concurrent conditions and	immunofluorescence	and	neutralization	titers	of	patients	with	IgM-positive California	
serogroup virus infections	in	Finland,	2001–2013* 
Patient	
no. 
IgG	IFA	
titer 
IgM	IFA	
titer PCR	result Underlying	illness Reason	for	medical	care 
PRNT	titer 
INKV CHATV TAHV 
1 160 160 Neg – Hospitalized	(unknown	infection)† 320 40 40 
2 80 40 Neg – Hospitalized	(unknown	infection)† 320 640‡ 40 
3 120 40 Neg – Hospitalized	(unknown	infection)† 320 40 40 
4 >640 >320 Neg Hypertension Hospitalized	(unknown	infection)† 320 20,480 5,120 
5§ 160 +/ND¶ ND – Hospitalized	(unknown	infection)† ND ND ND 
6§ 320 +/ND¶ ND – Hospitalized	(unknown	infection)† ND ND ND 
7 80 >320 Neg Type	2	diabetes,	
hypertension 
Fever	(unknown	infection)† >640 40 80 
8 320 40 Neg – No	information 320 <20 <20 
9 80 80 Neg Asthma, 
immunodeficiency 
No	information 160 40 <40 
10 40 20 ND Hypothyroidism Follow-up	visit	(suspected	MS,	
neurologic	disorder) 
160 20 40 
11 320 >320 Neg – Follow-up	visit	(recurrent	respiratory	
tract	infections	for	4	mo,	suspected	
immunodeficiency) 
320 40 80 
12 <20 40 Neg Schizophrenia,	
hypothyroidism 
Follow-up	visit	(HSV	eye	infection,	rash,	
Steven-Johnson	syndrome) 
320 20 40 
13 160 120 Neg – Hospitalized,	acute	infection	(E. coli 
urosepsis) 
160 40 40 
14 <20 120 Neg MS	disease,	
hypothyroidism 
Hospitalized,	acute	infection	(HSV	
infection) 
>640 <20 20 
15 320 120 Neg – Hospitalized, acute	infection	(impetigo	
contagiosa) 
640 40 40 
16 960 40 ND – Hospitalized,	multiple	infarcts	in	the	
central nervous system 
1,280 5,120 1,280 
17 80 30 Neg – Hospitalized,	epidemic	nephropathy 320 <20 <20 
*CHATV,	Chatanga	virus; HSV,	herpes	viruses;	IFA,	indirect	immunofluorescence;	INKV,	Inkoo	virus; MS,	multiple	sclerosis;	ND,	PCR	not	done;	PRNT,	
plaque	reduction	neutralization	test;	TAHV,	Tahyna virus;	–, no underlying illness.  
†Full	patient	history	describing	INKV	or	CHATV	infection. 
‡4-fold difference between titers was not achieved with	neutralization	test,	the	diagnostic	criterion	used	to	confirm	CHATV	infection. 
§INKV	infection	confirmed	by	hemagglutination inhibition	test	and	neutralization	test earlier	in	Helsinki	University	Central	Hospital	laboratory. 
¶Samples	tested	were	IgM	positive, but titer was not tested.  
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negligible here (Table 1). The lack of awareness regarding 
these infections is similar to the situation with California 
serogroup viruses in many other countries.
A few articles from Russia have described the outcome 
and neurologic characteristics of INKV infection (10–12). 
In these studies, most patients had fever; almost 30% had 
neurologic symptoms (11). Studies in the Ryazan area 
showed that INKV infection was most frequently found in 
adults 21–40 years of age, and the number of cases peaked 
during the 2 periods of May and early August (31). In our 
study, 88% of the INKV cases were found during August 
and September or even later; only 2 cases occurred in early 
summer, and most patients with acute infection were <16 
or 50–59 years of age. Another study from Russia included 
520 selected patients; overall, 9.8% had California sero-
group infection, with 2.5% and 1.2% INKV incidence in 
febrile and encephalitis patients, respectively (11). A more 
detailed study on the symptoms of the California serogroup 
infection included 118 patients, but INKV was confirmed 
in only 2 patients, 1 with multiple sclerosis and the other 
with meningoencephalitis (10). In that study, TAHV and 
undefined California serogroup infections (i.e., neutraliza-
tion tests found no difference between INKV and TAHV) 
occurred more frequently than INKV (10). However, dur-
ing 1995, the study period, CHATV had not yet been iso-
lated but, as we now know, was already circulating in the 
area (14). Consequently, these infections could have been 
caused by CHATV. 
Our study confirmed both INKV and CHATV infec-
tions in Finland. Most identified acute cases were from 
the Helsinki hospital district (Figure), possibly because 
most samples were collected in southern Finland, where 
the laboratory is located and where Finland’s population 
density is highest. The overrepresentation of samples from 
the southern region may have decreased the likelihood of 
finding acute cases because distribution of California se-
rogroup virus seroprevalence among humans is greater in 
northern Finland than in southern Finland, although the 
seroprevalence has recently increased in southern parts of 
the country (5,32). Furthermore, the high seroprevalence 
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Table 4. Clinical	progression	of	illness	for	patients	hospitalized	with	acute	INKV	(n	=	4)	or	CHATV	infection	(n	=	2),	Finland* 
Virus	and	patient	no. Illness progression Additional findings 
INKV   
 1 Day	1:	fever	38°C,	influenza-like symptoms Elevated	HHV-6	antibody	levels	from	same	sample 
 Day	3:	disoriented  
 Day	6:	hospitalized,	abnormal	EEG,	CAL	IgM+  
 Day	7:	psychotic	but	discharged  
 Day	10:	follow-up EEG shows same abnormalities  
 3	mo	later:	EEG	almost	normal  
 2 Day	1:	fever	39.5°C,	headache,	nuchal	rigidity,	sore	throat	
before	fever,	hospitalized 
Tick	bite	1	mo earlier,	erythema	migrans;	day	1:	
BorrAb	neg 
 Day	2:	nuchal	rigidity,	headache	deteriorating,	slowness	
but oriented 
 
 Day	3:	discharged,	CAL	IgM+  
 Day	5:	headache	again,	hospitalized  
 Day	6:	discharged  
 3 Day	1:	vomiting  
 Day	2:	stomach	pain,	diarrhea,	seizures,	 hospitalized  
 Day	3:	fever	38.3°C,	drowsiness,	convulsions  
 Day	4:	More	seizures,	small	changes	in	EEG  
 Day	5:	CAL	IgM+  
 Day	8:	discharged  
 4 Day	1:	fever	37.9°C,	sore	throat Tick	bite	3	wks	earlier 
 Day	3:	CAL	IgM+  
 Day 4:	nausea	and	vomiting  
 Day	5:	fever	39°C,	headache,	nuchal	rigidity,	hospitalized  
 Day	10:	recovered	and	discharged  
CHATV   
 1 Day	1:	vomiting	continuing	for	3	d  
 Day	4:	fever,	hospitalized,	disoriented	at	night  
 Day	7:	frontal	headache,	normal head	CT	and	abdominal	
ultrasound 
 
 Day	12:	discharged,	CAL	IgM+  
 2 Day	1:	fever	39°C,	back	pain Back	injury	2	wks	earlier 
 Day	7:	hospitalized,	high	fever,	back	pain	almost	resolved  
 Day	7–22:	temporal	pain,	trembling	of	hands,	fluctuating	
fever 
 
 Day	17:	CAL	IgM+  
 Day	23:	discharged  
*BorrAb,	Borrelia	antibody	test;	CHATV,	Chatanga	virus;	CT,	computer	tomographic	scan;	EEG,	electroencephalogram;	HHV,	human	herpesvirus;	INKV,	
Inkoo virus.	CAL	IgM+	indicates	the	day	when	IgM	for	California	encephalitis	group	viruses	was observed. 
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suggests that the serogroup viruses are found abundantly in 
nature and that infection is fairly common, so the frequency 
of acute cases we observed may underestimate the actual 
number of cases in Finland. Most acute cases occurred in 
autumn, yet the population density of the INKV principal 
vector, O. communis, is highest in June. Further studies are 
needed to determine whether this time lag reflects a long in-
cubation period, spillover to other vectors, replication cycle 
in amplification hosts, or a change in vector occurrence.
The high seroprevalence in Finland with the low fre-
quency of cases requiring healthcare and low frequency of 
diagnostic sampling suggests that most of these infections 
are subclinical or manifest as mild disease. On the other 
hand, the patient panels used in our study were highly se-
lected, so we could have missed INKV and CHATV cases 
among patients with other symptom patterns. In addition, 
the IgM IFA test used may not have been sensitive enough 
to detect IgM in all cases. The high seroprevalence in the 
populations in Finland may also be influenced by the new-
ly identified California serogroup virus isolate found here, 
the Chatanga virus Möhkö strain (13). Results from the 
diagnostic test in use show cross-reactions between the 
serogroup viruses. Most (82%) of the acute infections in 
this study were INKV cases, confirmed by using PRNT, 
which showed >4-fold titer differences, consistent with 
findings that INKV is the major California serogroup 
agent in seroprevalence studies in Finland and Sweden 
(33). Although most cases seem subclinical or mild, the 
data in our study indicate that the clinical disease may 
occasionally be severe; all children with acute illness had 
INKV infection and were hospitalized. Although INKV 
infection in adults was mild, 1 adult patient with CHATV 
infection required hospital care.
The considerable variation in IgG and IgM titers of 
serum samples from patients with acute infection may 
suggest that the samples were taken at different stages of 
the acute infection, but the differences may simply reflect 
variation in the antibody levels in individual patients. IgM 
was detectable in several patients concomitantly with high 
titers of IgG and neutralizing antibodies, a finding suggest-
ing that IgM may persist for several weeks. One patient 
had detectable IgM 17 days after symptom onset (Table 4). 
A follow-up sample would be needed to show seroconver-
sion and confirm the acute infection. No patient samples 
were collected during the viremic stage, and all samples 
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Table 5. Symptoms	of	acute	INKV	and	CHATV	infections, as 
recorded in charts of 7 patients hospitalized	with	unknown	
infection,	Finland* 
Symptom INKV, N =	5 CHATV, N	=	2 
Fever 5 2 
Influenza-like symptom 4 0 
Headache 4 2 
Nausea/vomiting 2 1 
Disorientation 2 1 
Sore	throat 2 0 
Nuchal	rigidity 2 0 
Changes	in	EEG 2 0 
Diarrhea 1 0 
Seizure 1 0 
Drowsiness 1 0 
*These	7	patients	were	hospitalized	with	unknown	infection	(Table	3),	
which	were	determined	to	be	Inkoo	virus	(INKV)	or	Chatanga	(CHATV)	
infections. Symptoms	are	listed	in	order	of	frequency.	EEG, 
electroencephalogram.  
 
Figure.	Locations	of	residence	for	17	patients	who	were	IgM	
positive	for	California	serogroup	virus	infections,	Finland.	Each	
dot	represents	1	patient	except	for	the	largest	dot	in	southern	
Finland,	which	indicates	a	site	for	6	patients.	The	dot	on	the	far	
left	indicates	a	patient	from	Åland	Islands,	Finland.	Map	source:	
National	Land	Survey	of	Finland	(©	2015).	A	color	version	
of	this	figure	is	available	online	(http://wwwnc.cdc.gov/EID/
article/22/5/15-1015-F.htm).
RESEARCH
were RT-PCR negative. Distinct LACV strains are known 
to cause different symptoms (34), but neither INKV nor 
CHATV have been isolated from a human sample. Human 
isolates or sequences of these viruses would be valuable for 
comparing the pathogenicity of the strains and analyzing 
cases in patients requiring hospitalization. 
Many of our cases appear to represent recent subclini-
cal infections that were identified only because of IgM test-
ing and were unrelated to the reason for patients’ visits to 
the healthcare unit. In the 2 patients with HSV cold sores, 
subclinical INKV infection could have triggered reactiva-
tion of HSV. Alternatively, INKV may require the pres-
ence of an underlying disease or trauma to cause a symp-
tomatic infection (e.g., by enabling the virus to cross the 
blood–brain barrier). Some reports from Russia suggest 
that certain concomitant microbial infections may render 
the course of the INKV infection more severe (11).
In conclusion, we describe INKV and CHATV infec-
tions in humans and the clinical characteristics of acute dis-
ease. Symptoms of acute INKV and CHATV infections in 
patients in our study resembled symptoms of other Califor-
nia serogroup virus infections: influenza-like illness, with 
fever being most prominent. Most acute cases appeared to 
be subclinical, and a small minority of patients required 
hospitalization. Compared with adults, children were at 
higher risk for contracting more severe disease and were 
more often hospitalized because of INKV infection. In 
adults, CHATV infection appeared to be more severe than 
INKV infection. Further studies are required to explore in 
detail the clinical picture, prognosis, incubation period, and 
antibody kinetics of these infections. Viral isolates or RT-
PCR–positive samples from patients are needed to acquire 
data related to INKV and CHATV strains causing the clini-
cal cases.
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Orthobunyavirus [orʺtho-bunʹyə-viʺrəs]
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The largest genus in the family Bunyaviridae, the genus Orthobunyavirus was originally named Bun-yavirus, for the type species Bunyamwera virus, first isolated in 1943 from the eponymous town in 
western Uganda. Originally, the vernacular term “bunyavi-
rus” was used for viruses in this genus, but as more genera 
were added to Bunyaviridae (there are currently 5), confu-
sion arose over whether “bunyavirus” referred to members 
of the genus Bunyavirus or family Bunyaviridae.
In 1995, the Bunyaviridae Study Group of the Interna-
tional Committee on Taxonomy of Viruses recommended 
adding the prefix “ortho-” (Greek for “correct”) to the ge-
nus name (C. Calisher, pers. comm.) to prevent confusion. 
Two orthobunyaviruses reported on in this issue of Emerg-
ing Infectious Diseases are Inkoo virus and Chatanga vi-
rus (named for the towns of Inkoo, Finland, and Khatanga, 
Russia, respectively, where they were first isolated).
This electron micrograph reveals the morphologic traits of the 
La	Cross	virus	(LCV),	a	Bunyaviridae	virus	family	member.	
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